Congestive heart failure other pharmacotherapies

Congestive heart failure Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Causes
Differentiating Congestive heart failure from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Clinical Assessment
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Cardiac MRI
Echocardiography
Exercise Stress Test
Myocardial Viability Studies
Cardiac Catheterization
Endomyocardial biopsy
Treatment
Invasive Hemodynamic Monitoring
Medical Therapy: Acute Pharmacotherapy Chronic Pharmacotherapy: Diuretics ACE Inhibitors Angiotensin receptor blockers Aldosterone Antagonists Beta Blockers Ca Channel Blockers Nitrates Hydralazine Positive Inotropics Anticoagulants Antiarrhythmic Drugs Nutritional Supplements Omega-3-Fatty Acid Hormonal Therapies Drugs to Avoid Drug Interactions Treatment of underlying causes Associated conditions
Exercise Training
Surgical Therapy: Biventricular Pacing or Cardiac Resynchronization Therapy (CRT) Implantation of Intracardiac Defibrillator Ultrafiltration Cardiac Surgery Left Ventricular Assist Devices (LVADs) Cardiac Transplantation
ACC/AHA Guideline Recommendations: Hospitalized Patients Patients With a Prior MI Sudden Cardiac Death Prevention Patients at high risk for developing heart failure (Stage A) Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B) Patients with current or prior symptoms of heart failure (Stage C) Patients with refractory end-stage heart failure (Stage D)
Implementation of Practice Guidelines
Congestive heart failure end-of-life considerations
Specific Groups: Special Populations Patients who have concomitant disorders Obstructive Sleep Apnea in the Patient with CHF
Congestive heart failure other pharmacotherapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Congestive heart failure other pharmacotherapies
CDC on Congestive heart failure other pharmacotherapies
Congestive heart failure other pharmacotherapies in the news
Blogs on Congestive heart failure other pharmacotherapies</small>
Directions to Hospitals Treating Congestive heart failure other pharmacotherapies
Risk calculators and risk factors for Congestive heart failure other pharmacotherapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2]

Overview

Nutritional supplements and hormonal supplements have not been proved to be of any benefit in patients with heart failure and reduced left ventricular ejection fraction.

2009 ACC/AHA Focused Update and 2005 Guidelines for the Diagnosis and Management of Chronic Heart Failure in the Adult (DO NOT EDIT)

Nutritional Supplements in Patients Presenting With Heart Failure (DO NOT EDIT)

Class III (No Benefit)

"1. Use of nutritional supplements as treatment for heart failure is not indicated in patients with current or prior symptoms of heart failure and reduced left ventricular ejection fraction (LVEF). (Level of Evidence: C) "

Hormonal Therapies in Patients Presenting With Heart Failure (DO NOT EDIT)

Class III (No Benefit)

"1. Hormonal therapies other than to replete deficiencies are not recommended and may be harmful to patients with current or prior symptoms of heart failure and reduced left ventricular ejection fraction (LVEF). (Level of Evidence: C) "

Vote on and Suggest Revisions to the Current Guidelines

• The CHF Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines

External Links

• The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult

• 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation